

Taiwan's OBI Pharma inks agreement US-based TegMine Therapeutics for glycan-targeting ADC

January 13, 2026 | News

Successful delivery of commissioned ADC candidate to advance the collaboration between OBI and TegMine



Taiwan based OBI Pharma has entered into a commercial license agreement with TegMine Therapeutics, Inc., a San Francisco-based biopharma focused on developing antibodies targeting cancer-associated glycans and glycoproteins, for a glycan-targeting antibody-drug conjugate (ADC).

Under the terms of the agreement, OBI is eligible to receive an upfront payment as well as development and commercial milestones. Following product launch, OBI will also receive royalties based on a tiered percentage of annual net sales. While the detailed financial terms are not disclosed in accordance with the confidentiality provisions, the overall deal economics are broadly comparable to those of recent similar licensing transactions in the market.

TegMine will obtain the exclusive global rights to develop and commercialize the ADC under the license agreement. This international licensing collaboration reflects the potential value of products generated using OBI's Obrion™ ADC technologies.

The licensed ADC candidate is derived from a high-affinity anti-glycan antibody provided by TegMine and was developed into an ADC by OBI using the Obrion™ ADC technology family, including the GlycOBI® glycan-conjugation technology, the dual-function enzymatic EndoSymeOBI®, and the highly hydrophilic linker HYPrOBI®. The ADC candidate generated with this proprietary site-specific glycan conjugation is homogeneous and scalable for manufacturing.